Samsung Biologics has completed a messenger ribonucleic acid (mRNA) vaccine substance manufacturing line at its Songdo site in Incheon, securing the ability to fully handle production processes for the temperature-sensitive vaccine from substance manufacturing to finished product packaging.

According to sources on Thursday, Samsung Biologics recently started producing Covid-19 vaccine substance for U.S.-based GreenLight Biosciences in the new line at the end of May.

The addition of mRNA vaccine substance production line, Samsung Biologics is now able to provide one-stop services to customers from substance production to aseptic filling, labeling and packaging, including manufacturing and encapsulation of lipid nanoparticles, which is important for mRNA vaccine production.

Last year, the company announced it will expand its facility to be able to produce vaccine stock solution on top of its fill-finish capability for Moderna’s Covid-19 vaccine.

At the end of last year, Samsung Biologics won a deal for vaccine substance production from GreenLight Biosciences.

Shares of Samsung Biologics were trading slightly higher at 848,000 won ($677) on Thursday.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]